KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Current Leases (2016 - 2025)

Nektar Therapeutics has reported Current Leases over the past 13 years, most recently at $20.5 million for Q4 2025.

  • Quarterly results put Current Leases at $20.5 million for Q4 2025, up 3.16% from a year ago — trailing twelve months through Dec 2025 was $20.5 million (up 3.16% YoY), and the annual figure for FY2025 was $20.5 million, up 3.16%.
  • Current Leases for Q4 2025 was $20.5 million at Nektar Therapeutics, down from $22.2 million in the prior quarter.
  • Over the last five years, Current Leases for NKTR hit a ceiling of $22.2 million in Q3 2025 and a floor of $15.8 million in Q1 2021.
  • Median Current Leases over the past 5 years was $19.3 million (2023), compared with a mean of $19.5 million.
  • Biggest five-year swings in Current Leases: grew 25.34% in 2021 and later fell 5.56% in 2023.
  • Nektar Therapeutics' Current Leases stood at $17.4 million in 2021, then increased by 7.03% to $18.7 million in 2022, then grew by 3.17% to $19.3 million in 2023, then rose by 3.16% to $19.9 million in 2024, then grew by 3.16% to $20.5 million in 2025.
  • The last three reported values for Current Leases were $20.5 million (Q4 2025), $22.2 million (Q3 2025), and $22.0 million (Q2 2025) per Business Quant data.